Equities Analysts Set Expectations for argenx SE -‘s FY2018 Earnings (ARGX)

argenx SE – (NASDAQ:ARGX) – Stock analysts at Wedbush lifted their FY2018 EPS estimates for shares of argenx in a report issued on Monday, October 29th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($2.25) per share for the year, up from their prior estimate of ($2.80). Wedbush currently has a “Positive” rating and a $121.00 target price on the stock. Wedbush also issued estimates for argenx’s Q4 2018 earnings at ($0.90) EPS, FY2019 earnings at ($5.68) EPS, FY2020 earnings at ($7.72) EPS and FY2021 earnings at ($6.63) EPS.

A number of other brokerages have also recently commented on ARGX. Stifel Nicolaus started coverage on argenx in a research note on Thursday, September 13th. They set a “buy” rating and a $139.00 price objective on the stock. Piper Jaffray Companies reiterated an “overweight” rating and issued a $154.00 price target on shares of argenx in a research note on Monday, September 17th. Evercore ISI started coverage on argenx in a research note on Monday, October 15th. They issued an “outperform” rating and a $110.00 price target on the stock. JMP Securities boosted their price target on argenx to $150.00 and gave the stock an “outperform” rating in a research note on Monday, September 17th. Finally, SunTrust Banks boosted their price target on argenx to $132.00 and gave the stock an “in-line” rating in a research note on Tuesday, September 18th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $130.50.

ARGX stock opened at $80.01 on Thursday. The stock has a market cap of $2.41 billion, a price-to-earnings ratio of -57.15 and a beta of 2.38. argenx has a 12-month low of $22.21 and a 12-month high of $103.00.

Large investors have recently bought and sold shares of the company. Atria Investments LLC bought a new position in shares of argenx during the second quarter valued at approximately $213,000. Fred Alger Management Inc. grew its holdings in shares of argenx by 50.0% during the second quarter. Fred Alger Management Inc. now owns 3,000 shares of the company’s stock valued at $249,000 after purchasing an additional 1,000 shares during the last quarter. Clear Harbor Asset Management LLC bought a new position in shares of argenx during the third quarter valued at approximately $326,000. Dimensional Fund Advisors LP bought a new position in shares of argenx during the first quarter valued at approximately $498,000. Finally, Jane Street Group LLC bought a new position in shares of argenx during the first quarter valued at approximately $619,000. 55.95% of the stock is owned by institutional investors.

About argenx

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Featured Article: Why do companies engage in swaps?

Earnings History and Estimates for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply